Recent Advances in Cell Membrane-Derived Biomimetic Nanotechnology for Cancer Immunotherapy

Purpose: Cancer immunotherapy is limited by the immunosuppressive tumor microenvironment, patient heterogeneity, poor delivery of immunotherapeutics, and systemic immunotoxicity. Cell membrane-derived biomimetic nanoparticles may improve delivery and biodistribution, enhance targeting and immune stimulation, and overcome barriers faced by conventional nanomedicine.

Hypothesis: No formal experimental hypothesis. Central thesis: coating synthetic nanoparticles with natural cell membranes—from red blood cells, cancer cells, white blood cells, platelets, or hybrid membranes—can combine natural cell functions with engineered nanocarriers to achieve prolonged circulation, immune evasion, tumor targeting, antigen presentation, and responsive drug release for more effective and safer cancer immunotherapy.

Aims: Review the background of cancer immunotherapy and biomimetic nanotechnology. - Discuss design parameters of biomimetic nanoparticles for efficient cancer immunotherapy. - Highlight recent applications of cell-derived biomimetic nanotechnology, including RBC, cancer cell, WBC, platelet, and hybrid membranes. - Address challenges and future prospects for clinical translation.

Delivery system: Biomimetic platforms: cell membrane-coated nanoparticles, nanovesicles, nanoghosts, nanogels, liposomes/micelles, artificial antigen-presenting cells (aAPCs). - Membrane sources: red blood cell membrane (RBCM), cancer cell membrane (CCM), white blood cell membrane (WBCM; leukocytes, macrophages, neutrophils, NK/T cells), platelet membrane, hybrid membranes. - Core materials: PLGA, mesoporous silica nanoparticles (MSNs), magnetic nanoclusters (Fe₃O₄), black phosphorus quantum dots, gold nanostructures, nanoliposomes, polymeric micelles, nanogels, copper sulfide nanoparticles. - Payloads: tumor antigens (tumor lysate, neoantigens, hgp10025-33, Neu5Gc), adjuvants (MPLA, CpG-ODN, R837, mannose), immune checkpoint inhibitors (anti-PD-1, anti-PD-L1, anti-CTLA-4), cytokines (IL-2, IL-15), photosensitizers (TCPP, pheophorbide A), chemotherapeutics (DOX, PTX, paclitaxel dimer, gemcitabine, cyclophosphamide). - Targeting/functionalization: mannose, anti-CD205, cRGD, folate, transferrin, iRGD, TAT, magnetic guidance, pH/enzyme/redox/NIR-responsive release. - Routes: intravenous, subcutaneous, local/post-surgical.

Approach: Review of preclinical literature; no primary experiments. Discusses in vitro cell lines and in vivo mouse tumor models, including B16F10 melanoma, 4T1 breast cancer, U87 glioblastoma, lymphoma, triple-negative breast cancer, and metastatic models. The review synthesizes design principles, membrane sources, and applications for immune checkpoint blockade, cancer vaccines, cytokine therapy, adoptive cell therapy, and combination therapy.

Key methods: Nanoparticle characterization: size, zeta potential, morphology (TEM), core-shell structure, membrane protein retention. - Cellular uptake and immune cell interaction: flow cytometry, confocal microscopy, APC uptake, DC maturation. - Immune response: CD4⁺/CD8⁺ T cell populations, IFN-γ secretion, cytokine production, tetramer staining, CTL-mediated killing. - In vivo efficacy: tumor growth inhibition, survival, metastasis inhibition, recurrence prevention, biodistribution/imaging (NIR, MRI). - Membrane characterization: SDS-PAGE, Western blot, proteomics.

Key results: RBCM-coated nanoparticles improved half-life by up to 50% versus PEGylated nanoparticles and were detected in blood circulation after 72 h. - A size-reducible RBCM biomimetic system combined with PDT/chemotherapy/anti-PD-L1 achieved up to 84.2% cancer cell inhibition with metastasis elimination. - Hybrid RBC–cancer cell membrane micelles (DH@ECm) achieved 64% tumor inhibition and elevated CD8⁺ T cells in a 4T1 tumor model. - Mannose-modified RBCM-coated PLGA nanovaccine enhanced antigen retention in draining lymph nodes, inhibited melanoma growth and metastasis, and increased CD8⁺ T cell infiltration and IFN-γ secretion. - RBC-based aAPC-IL2 induced antigen-specific CD8⁺ T cell proliferation and cancer cell-specific lysis. - Platelet membrane-coated Fe₃O₄-SAS nanoparticles improved PD-1 blockade and inhibited metastatic tumors in a 4T1 model.

Interpretation: Cell membrane-derived biomimetic nanotechnology offers a promising top-down strategy to improve cancer immunotherapy by integrating natural membrane functions—immune evasion, prolonged circulation, homotypic targeting, antigen presentation—with synthetic nanocarrier versatility. These systems can enhance immune response, reduce toxicity, and enable personalized immunotherapy. However, clinical translation requires further optimization, standardized manufacturing, and safety evaluation.

Limitations: Review article; no primary data. - Most studies are preclinical; clinical validation is limited. - Complex preparation, low yield, difficult scale-up, and challenging preservation/storage. - Lack of standardized protocols for membrane preparation, quality control, and immunogenicity assessment. - Membrane integrity and coating stability during circulation must be ensured. - Source cell genetic material must be removed, especially for cancer cell membranes. - Protein corona can mask targeting ligands and alter biodistribution. - Tumor penetration, extracellular matrix barriers, and tumor heterogeneity remain challenges. - Homotypic targeting has mainly been shown with commercial cell lines; proof with resected patient cancer cells is needed. - GMP manufacturing and cost-effective production are required for clinical translation.